T 2344/19 (Vortioxetine/LUNDBECK) of 05.04.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T234419.20220405
- Date of decision
- 5 April 2022
- Case number
- T 2344/19
- Petition for review of
- -
- Application number
- 11749331.2
- IPC class
- A61P 25/00A61K 31/495
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)PHENYL]PIPERAZINE
- Applicant name
- H. Lundbeck A/S
- Opponent name
- Hexal AG
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56
- Keywords
- Novelty - new patient group (yes)
Inventive step - (yes) - Catchword
- -
- Cited cases
- T 1491/14
- Citing cases
- T 0136/24
Order
For these reasons it is decided that:
- The decision under appeal is set aside;
- The case is remitted to the opposition division with the order to maintain the patent in amended form with the following claims and a description possibly adapted thereto:
Claims 1 to 4 of the main request submitted as auxiliary request 2 with the statement of grounds of appeal.